{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:11:47Z","timestamp":1792444307427,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12881-015-0262-2","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T03:10:03Z","timestamp":1452913803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma"],"prefix":"10.1186","volume":"17","author":[{"given":"Nat\u00e1lia","family":"Bertoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lied M. S.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio E.","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston B.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia P.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,15]]},"reference":[{"issue":"5","key":"262_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/jclinpath-2011-200462","volume":"65","author":"T Itinteang","year":"2012","unstructured":"Itinteang T, Tan ST, Brasch HD, Steel R, Best HA, Vishvanath A, et al. Infantile haemangioma expresses embryonic stem cell markers. J Clin Pathol. 2012;65(5):394\u20138.","journal-title":"J Clin Pathol"},{"issue":"5","key":"262_CR2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.pcl.2010.07.008","volume":"57","author":"KE Holland","year":"2010","unstructured":"Holland KE, Drolet BA. Infantile hemangioma. Pediatr Clin North Am. 2010;57(5):1069\u201383.","journal-title":"Pediatr Clin North Am"},{"issue":"5\u20136","key":"262_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0945-053X(01)00150-0","volume":"20","author":"M Vikkula","year":"2001","unstructured":"Vikkula M, Boon LM, Mulliken JB. Molecular genetics of vascular malformations. Matrix Biol. 2001;20(5\u20136):327\u201335.","journal-title":"Matrix Biol"},{"issue":"2","key":"262_CR4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1542\/peds.2007-2767","volume":"122","author":"LC Chang","year":"2008","unstructured":"Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360\u20137.","journal-title":"Pediatrics"},{"issue":"6","key":"262_CR5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jpeds.2011.12.026","volume":"160","author":"BA Drolet","year":"2012","unstructured":"Drolet BA, Pope E, Juern AM, Sato T, Howell B, Puttgen KB, et al. Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas. J Pediatr. 2012;160(6):1021\u20136. e1023.","journal-title":"J Pediatr"},{"issue":"7","key":"262_CR6","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archderm.139.7.869","volume":"139","author":"M Waner","year":"2003","unstructured":"Waner M, North PE, Scherer KA, Frieden IJ, Waner A, Mihm MC. The nonrandom distribution of facial hemangiomas. Arch Dermatol. 2003;139(7):869\u201375.","journal-title":"Arch Dermatol"},{"issue":"2","key":"262_CR7","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1542\/peds.2010-0029","volume":"128","author":"M Hogeling","year":"2011","unstructured":"Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259\u201366.","journal-title":"Pediatrics"},{"issue":"24","key":"262_CR8","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque DE, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"262_CR9","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1073\/pnas.102185799","volume":"99","author":"MR Ritter","year":"2002","unstructured":"Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A. 2002;99(11):7455\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"262_CR10","doi-asserted-by":"crossref","unstructured":"Spock CL, Tom LK, Canadas K, Sue GR, Sawh-Martinez R, Maier CL, et al. Infantile hemangiomas exhibit neural crest and pericyte markers. Ann Plast Surg. 2014.","DOI":"10.1097\/SAP.0000000000000080"},{"issue":"11","key":"262_CR11","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/PAS.0b013e3181f6076f","volume":"34","author":"AR Huu Le","year":"2010","unstructured":"Le Huu AR, Jokinen CH, Rubin BP, Ruben BP, Mihm MC, Weiss SW, et al. Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma. Am J Surg Pathol. 2010;34(11):1563\u201373.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"262_CR12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/modpathol.3800153","volume":"17","author":"SS Dadras","year":"2004","unstructured":"Dadras SS, North PE, Bertoncini J, Mihm MC, Detmar M. Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol. 2004;17(9):1068\u201379.","journal-title":"Mod Pathol"},{"issue":"6","key":"262_CR13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/labinvest.2008.32","volume":"88","author":"SD Boyd","year":"2008","unstructured":"Boyd SD. Everything you wanted to know about small RNA but were afraid to ask. Lab Invest. 2008;88(6):569\u201378.","journal-title":"Lab Invest"},{"issue":"7","key":"262_CR14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","volume":"5","author":"L He","year":"2004","unstructured":"He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522\u201331.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"262_CR15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/bdrc.20073","volume":"78","author":"G Leva Di","year":"2006","unstructured":"Di Leva G, Calin GA, Croce CM. MicroRNAs: fundamental facts and involvement in human diseases. Birth Defects Res C Embryo Today. 2006;78(2):180\u20139.","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"2","key":"262_CR16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"issue":"4","key":"262_CR17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.gde.2005.06.012","volume":"15","author":"BD Harfe","year":"2005","unstructured":"Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev. 2005;15(4):410\u20135.","journal-title":"Curr Opin Genet Dev"},{"issue":"46","key":"262_CR18","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1038\/sj.onc.1209914","volume":"25","author":"JM Cummins","year":"2006","unstructured":"Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006;25(46):6220\u20137.","journal-title":"Oncogene"},{"issue":"2","key":"262_CR19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10428190601059738","volume":"48","author":"A Rinaldi","year":"2007","unstructured":"Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, et al. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma. 2007;48(2):410\u20132.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"262_CR20","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1074\/jbc.M707224200","volume":"283","author":"LB Frankel","year":"2008","unstructured":"Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283(2):1026\u201333.","journal-title":"J Biol Chem"},{"key":"262_CR21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1476-4598-9-238","volume":"9","author":"PP Reis","year":"2010","unstructured":"Reis PP, Tomenson M, Cervigne NK, Machado J, Jurisica I, Pintilie M, et al. Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Mol Cancer. 2010;9:238.","journal-title":"Mol Cancer"},{"issue":"Database issue","key":"262_CR22","doi-asserted-by":"crossref","first-page":"D68","DOI":"10.1093\/nar\/gkt1181","volume":"42","author":"A Kozomara","year":"2014","unstructured":"Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68\u201373.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"262_CR23","doi-asserted-by":"crossref","first-page":"D152","DOI":"10.1093\/nar\/gkq1027","volume":"39","author":"A Kozomara","year":"2011","unstructured":"Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39(Database issue):D152\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"262_CR24","first-page":"D154","volume":"36","author":"S Griffiths-Jones","year":"2008","unstructured":"Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36(Database issue):D154\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"262_CR25","doi-asserted-by":"crossref","first-page":"D140","DOI":"10.1093\/nar\/gkj112","volume":"34","author":"S Griffiths-Jones","year":"2006","unstructured":"Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(Database issue):D140\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"262_CR26","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkh023","volume":"32","author":"S Griffiths-Jones","year":"2004","unstructured":"Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004;32(Database issue):D109\u201311.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"262_CR27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrc3166","volume":"11","author":"AL Kasinski","year":"2011","unstructured":"Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"262_CR28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"262_CR29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","volume":"18","author":"X Chen","year":"2008","unstructured":"Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997\u20131006.","journal-title":"Cell Res"},{"issue":"30","key":"262_CR30","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","volume":"105","author":"PS Mitchell","year":"2008","unstructured":"Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"262_CR31","doi-asserted-by":"crossref","first-page":"19097","DOI":"10.1073\/pnas.0509579102","volume":"102","author":"CM Barn\u00e9s","year":"2005","unstructured":"Barn\u00e9s CM, Huang S, Kaipainen A, Sanoudou D, Chen EJ, Eichler GS, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A. 2005;102(52):19097\u2013102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"262_CR32","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2353\/ajpath.2009.080517","volume":"174","author":"ML Calicchio","year":"2009","unstructured":"Calicchio ML, Collins T, Kozakewich HP. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol. 2009;174(5):1638\u201349.","journal-title":"Am J Pathol"},{"issue":"2","key":"262_CR33","doi-asserted-by":"crossref","first-page":"231e","DOI":"10.1097\/PRS.0000000000000367","volume":"134","author":"C Jiang","year":"2014","unstructured":"Jiang C, Lin X, Hu X, Chen H, Jin Y, Ma G, et al. Angiogenin: a potential serum marker of infantile hemangioma revealed by cDNA microarray analysis. Plast Reconstr Surg. 2014;134(2):231e\u20139e.","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"262_CR34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2045-824X-5-6","volume":"5","author":"JM Stiles","year":"2013","unstructured":"Stiles JM, Rowntree RK, Amaya C, Diaz D, Kokta V, Mitchell DC, et al. Gene expression analysis reveals marked differences in the transcriptome of infantile hemangioma endothelial cells compared to normal dermal microvascular endothelial cells. Vasc Cell. 2013;5(1):6.","journal-title":"Vasc Cell"},{"issue":"3","key":"262_CR35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4161\/derm.26739","volume":"5","author":"SM Todorovich","year":"2013","unstructured":"Todorovich SM, Khan ZA. Elevated T-box 2 in infantile hemangioma stem cells maintains an adipogenic differentiation-competent state. Dermatoendocrinol. 2013;5(3):352\u20137.","journal-title":"Dermatoendocrinol"},{"issue":"1","key":"262_CR36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10456-009-9161-5","volume":"13","author":"JK Wu","year":"2010","unstructured":"Wu JK, Adepoju O, De Silva D, Baribault K, Boscolo E, Bischoff J, et al. A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis. 2010;13(1):15\u201323.","journal-title":"Angiogenesis"},{"issue":"7\u201312","key":"262_CR37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2119\/2004-00045.Bischoff","volume":"10","author":"Y Yu","year":"2004","unstructured":"Yu Y, Wylie-Sears J, Boscolo E, Mulliken JB, Bischoff J. Genomic imprinting of IGF2 is maintained in infantile hemangioma despite its high level of expression. Mol Med. 2004;10(7\u201312):117\u201323.","journal-title":"Mol Med"},{"issue":"9","key":"262_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050184","volume":"5","author":"A Ramasamy","year":"2008","unstructured":"Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 2008;5(9), e184.","journal-title":"PLoS Med"},{"issue":"12","key":"262_CR39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014334","volume":"5","author":"T Nakashima","year":"2010","unstructured":"Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, et al. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One. 2010;5(12), e14334.","journal-title":"PLoS One"},{"issue":"3","key":"262_CR40","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123\u201330.","journal-title":"Open Med"},{"issue":"2","key":"262_CR41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017429","volume":"6","author":"EA Shirdel","year":"2011","unstructured":"Shirdel EA, Xie W, Mak TW, Jurisica I. NAViGaTing the micronome--using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PLoS One. 2011;6(2), e17429.","journal-title":"PLoS One"},{"issue":"16","key":"262_CR42","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1093\/bioinformatics\/bti551","volume":"21","author":"S Maere","year":"2005","unstructured":"Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21(16):3448\u20139.","journal-title":"Bioinformatics"},{"issue":"18","key":"262_CR43","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1093\/nar\/28.18.3442","volume":"28","author":"B Snel","year":"2000","unstructured":"Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 2000;28(18):3442\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"262_CR44","doi-asserted-by":"crossref","first-page":"D808","DOI":"10.1093\/nar\/gks1094","volume":"41","author":"A Franceschini","year":"2013","unstructured":"Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808\u201315.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"262_CR45","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504.","journal-title":"Genome Res"},{"issue":"11","key":"262_CR46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nmeth.2212","volume":"9","author":"R Saito","year":"2012","unstructured":"Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, et al. A travel guide to Cytoscape plugins. Nat Methods. 2012;9(11):1069\u201376.","journal-title":"Nat Methods"},{"issue":"12","key":"262_CR47","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nmeth.2689","volume":"10","author":"M Griffith","year":"2013","unstructured":"Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, et al. DGIdb: mining the druggable genome. Nat Methods. 2013;10(12):1209\u201310.","journal-title":"Nat Methods"},{"issue":"3","key":"262_CR48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","volume":"4","author":"MV Iorio","year":"2012","unstructured":"Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143\u201359.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"262_CR49","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10456-009-9148-2","volume":"12","author":"E Boscolo","year":"2009","unstructured":"Boscolo E, Bischoff J. Vasculogenesis in infantile hemangioma. Angiogenesis. 2009;12(2):197\u2013207.","journal-title":"Angiogenesis"},{"issue":"9","key":"262_CR50","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.ATV.0000137390.56554.df","volume":"24","author":"JC Tille","year":"2004","unstructured":"Tille JC, Pepper MS. Hereditary vascular anomalies: new insights into their pathogenesis. Arterioscler Thromb Vasc Biol. 2004;24(9):1578\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"52","key":"262_CR51","volume":"2","author":"JE Fish","year":"2009","unstructured":"Fish JE, Srivastava D. MicroRNAs: opening a new vein in angiogenesis research. Sci Signal. 2009;2(52), e1.","journal-title":"Sci Signal"},{"issue":"6","key":"262_CR52","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI117241","volume":"93","author":"K Takahashi","year":"1994","unstructured":"Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(6):2357\u201364.","journal-title":"J Clin Invest"},{"issue":"3","key":"262_CR53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.onc.1208223","volume":"24","author":"K Kishimoto","year":"2005","unstructured":"Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 2005;24(3):445\u201356.","journal-title":"Oncogene"},{"issue":"9","key":"262_CR54","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1158\/0008-5472.CAN-14-2394","volume":"75","author":"DJ Drasin","year":"2015","unstructured":"Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, et al. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res. 2015;75(9):1908\u201321.","journal-title":"Cancer Res"},{"issue":"1","key":"262_CR55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-7-13","volume":"7","author":"Y Ji","year":"2014","unstructured":"Ji Y, Chen S, Li K, Li L, Xu C, Xiang B. Signaling pathways in the development of infantile hemangioma. J Hematol Oncol. 2014;7(1):13.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"262_CR56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ncb2024","volume":"12","author":"L Ma","year":"2010","unstructured":"Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC\/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247\u201356.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"262_CR57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-014-3069-5","volume":"147","author":"JM Gwak","year":"2014","unstructured":"Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat. 2014;147(1):39\u201349.","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR58","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopha.2015.02.020","volume":"71","author":"X Ying","year":"2015","unstructured":"Ying X, Li-Ya Q, Feng Z, Yin W, Ji-Hong L. MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. Biomed Pharmacother. 2015;71:64\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"262_CR59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126837","volume":"10","author":"Y Oztemur","year":"2015","unstructured":"Oztemur Y, Bekmez T, Aydos A, Yulug IG, Bozkurt B, Dedeoglu BG. A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer. PLoS One. 2015;10(5), e0126837.","journal-title":"PLoS One"},{"key":"262_CR60","doi-asserted-by":"crossref","unstructured":"Dai Y, Wang D, Tian X, Zhang L, Sui C, Meng F, et al. Insights into the application of let-7 family as promising biomarker in cancer screening. Tumour Biol. 2015.","DOI":"10.1007\/s13277-015-3180-1"},{"issue":"1","key":"262_CR61","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molonc.2013.10.001","volume":"8","author":"SK Leivonen","year":"2014","unstructured":"Leivonen SK, Sahlberg KK, M\u00e4kel\u00e4 R, Due EU, Kallioniemi O, B\u00f8rresen-Dale AL, et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 2014;8(1):93\u2013104.","journal-title":"Mol Oncol"},{"issue":"8","key":"262_CR62","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/1535-7163.MCT-12-0975","volume":"12","author":"SU Haque","year":"2013","unstructured":"Haque SU, Dashwood MR, Heetun M, Shiwen X, Farooqui N, Ramesh B, et al. Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther. 2013;12(8):1556\u201367.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"262_CR63","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00280-014-2432-x","volume":"73","author":"IR Younis","year":"2014","unstructured":"Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, et al. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemother Pharmacol. 2014;73(5):991\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"262_CR64","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/bjc.2011.515","volume":"106","author":"G Groenewegen","year":"2012","unstructured":"Groenewegen G, Walraven M, Vermaat J, de Gast B, Witteveen E, Giles R, et al. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br J Cancer. 2012;106(2):284\u20139.","journal-title":"Br J Cancer"},{"issue":"4","key":"262_CR65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426\u201335.","journal-title":"Lancet Oncol"},{"issue":"11","key":"262_CR66","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-13-3448","volume":"20","author":"PJ Beltran","year":"2014","unstructured":"Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res. 2014;20(11):2947\u201358.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"262_CR67","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdu517","volume":"26","author":"GV Scagliotti","year":"2015","unstructured":"Scagliotti GV, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol. 2015;26(3):497\u2013504.","journal-title":"Ann Oncol"},{"issue":"3","key":"262_CR68","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00280-013-2240-8","volume":"72","author":"T Doi","year":"2013","unstructured":"Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, et al. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2013;72(3):643\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"262_CR69","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cam4.263","volume":"3","author":"EH Lin","year":"2014","unstructured":"Lin EH, Lenz HJ, Saleh MN, Mackenzie MJ, Knost JA, Pathiraja K, et al. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med. 2014;3(4):988\u201397.","journal-title":"Cancer Med"},{"key":"262_CR70","doi-asserted-by":"crossref","unstructured":"Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, et al. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015.","DOI":"10.1093\/annonc\/mdv171"},{"issue":"1","key":"262_CR71","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12885-015-1443-2","volume":"15","author":"K Takayoshi","year":"2015","unstructured":"Takayoshi K, Sagara K, Uchino K, Kusaba H, Sakamoto N, Iguchi A, et al. A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC Cancer. 2015;15(1):426.","journal-title":"BMC Cancer"},{"issue":"13","key":"262_CR72","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1245\/s10434-015-4597-x","volume":"22","author":"PM Spanheimer","year":"2015","unstructured":"Spanheimer PM, Lorenzen AW, De Andrade JP, Kulak MV, Carr JC, Woodfield GW, et al. Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. Ann Surg Oncol. 2015;22(13):4287\u201394. doi: 10.1245\/s10434-015-4597-x .","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"262_CR73","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-015-2694-y","volume":"75","author":"N Tebbutt","year":"2015","unstructured":"Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, et al. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015;75(5):993\u20131004.","journal-title":"Cancer Chemother Pharmacol"},{"key":"262_CR74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2045-824X-3-16","volume":"3","author":"K Mross","year":"2011","unstructured":"Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, et al. Phase I study of telatinib (BAY 57\u20139352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. Vasc Cell. 2011;3:16.","journal-title":"Vasc Cell"},{"key":"262_CR75","doi-asserted-by":"crossref","unstructured":"Chuma M, Terashita K, Sakamoto N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol Res. 2014.","DOI":"10.1111\/hepr.12459"},{"issue":"18","key":"262_CR76","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.3748\/wjg.v21.i18.5445","volume":"21","author":"XS Qi","year":"2015","unstructured":"Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol. 2015;21(18):5445\u201353.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"262_CR77","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00280-015-2751-6","volume":"75","author":"R D\u2019Alessandro","year":"2015","unstructured":"D\u2019Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, et al. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol. 2015;75(6):1237\u201345.","journal-title":"Cancer Chemother Pharmacol"},{"key":"262_CR78","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.8","volume":"4","author":"P Stiuso","year":"2015","unstructured":"Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, et al. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Mol Ther Nucleic Acids. 2015;4, e233.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"262_CR79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119765","volume":"10","author":"Z Mirza","year":"2015","unstructured":"Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Chaudhary AG, et al. Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics. PLoS One. 2015;10(3), e0119765.","journal-title":"PLoS One"},{"key":"262_CR80","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OTT.S68773","volume":"7","author":"P Wang","year":"2014","unstructured":"Wang P, Song L, Ge H, Jin P, Jiang Y, Hu W, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014;7:1761\u20138.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"262_CR81","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-014-2481-1","volume":"74","author":"M Mita","year":"2014","unstructured":"Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, et al. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(1):195\u2013204.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"262_CR82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2014.12.027","volume":"358","author":"N Awasthi","year":"2015","unstructured":"Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett. 2015;358(1):59\u201366.","journal-title":"Cancer Lett"},{"issue":"6","key":"262_CR83","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdv133","volume":"26","author":"G Deplanque","year":"2015","unstructured":"Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015;26(6):1194\u2013200.","journal-title":"Ann Oncol"},{"issue":"2","key":"262_CR84","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-014-2499-4","volume":"74","author":"T Dragovich","year":"2014","unstructured":"Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, et al. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74(2):379\u201387.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"262_CR85","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1535-7163.MCT-12-0907","volume":"12","author":"S Ponnurangam","year":"2013","unstructured":"Ponnurangam S, Standing D, Rangarajan P, Subramaniam D. Tandutinib inhibits the Akt\/mTOR signaling pathway to inhibit colon cancer growth. Mol Cancer Ther. 2013;12(5):598\u2013609.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"262_CR86","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1470-2045(15)70105-1","volume":"16","author":"JY Blay","year":"2015","unstructured":"Blay JY, Shen L, Kang YK, Rutkowski P, Qin S, Nosov D, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol. 2015;16(5):550\u201360.","journal-title":"Lancet Oncol"},{"key":"262_CR87","doi-asserted-by":"crossref","unstructured":"Minguet J, Smith KH, Bramlage CP, Bramlage P. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. Cancer Chemother Pharmacol. 2015.","DOI":"10.1007\/s00280-015-2770-3"},{"issue":"6","key":"262_CR88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.7150\/jca.11566","volume":"6","author":"A Grassadonia","year":"2015","unstructured":"Grassadonia A, Caporale M, Tinari N, Zilli M, DeTursi M, Gamucci T, et al. Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review. J Cancer. 2015;6(6):575\u201382.","journal-title":"J Cancer"},{"key":"262_CR89","doi-asserted-by":"crossref","unstructured":"Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, et al. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res. 2015.","DOI":"10.1111\/pcmr.12376"},{"key":"262_CR90","doi-asserted-by":"crossref","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015.","DOI":"10.1002\/cncr.29395"},{"key":"262_CR91","doi-asserted-by":"crossref","unstructured":"Haas RL, Gelderblom H, Sleijfer S, van Boven HH, Scholten A, Dewit L, et al. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities. Acta Oncol. 2015;1\u20137.","DOI":"10.3109\/0284186X.2015.1037404"},{"key":"262_CR92","first-page":"461823","volume":"2015","author":"A Souza De","year":"2015","unstructured":"De Souza A, Daly KP, Yoo J, Saif MW. Safety and efficacy of combined yttrium 90 resin radioembolization with aflibercept and folfiri in a patient with metastatic colorectal cancer. Case Rep Oncol Med. 2015;2015:461823.","journal-title":"Case Rep Oncol Med"},{"issue":"7","key":"262_CR93","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s12032-015-0638-3","volume":"32","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, et al. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol. 2015;32(7):638.","journal-title":"Med Oncol"},{"issue":"11","key":"262_CR94","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdu392","volume":"25","author":"F Selle","year":"2014","unstructured":"Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, et al. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. Ann Oncol. 2014;25(11):2191\u20136.","journal-title":"Ann Oncol"},{"issue":"6","key":"262_CR95","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11912-015-0448-y","volume":"17","author":"LC Villaruz","year":"2015","unstructured":"Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep. 2015;17(6):448.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"262_CR96","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ccr.2014.04.019","volume":"25","author":"JM Llovet","year":"2014","unstructured":"Llovet JM. Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. Cancer Cell. 2014;25(5):560\u20132.","journal-title":"Cancer Cell"},{"issue":"1","key":"262_CR97","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.4081\/hr.2015.5704","volume":"7","author":"UH Patel","year":"2015","unstructured":"Patel UH, Mir MA, Sivik JK, Raheja D, Pandey MK, Talamo G. Central neurotoxicity of immunomodulatory drugs in multiple myeloma. Hematol Rep. 2015;7(1):5704.","journal-title":"Hematol Rep"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-015-0262-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T19:56:49Z","timestamp":1654113409000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2350\/17\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1186\/s12881-015-0262-2","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,15]]},"article-number":"4"}}